2024-09-03 - Analysis Report
##  ABBV Stock Analysis Report

**Company:** AbbVie Inc. is a research-based global biopharmaceutical company with a leading portfolio of therapies for patients with serious and chronic illnesses.

**1. Performance Comparison:**

ABBV has outperformed the S&P 500 (VOO) with a cumulative return of 106.38% compared to VOO's 89.66%. This translates to a 16.72% difference in cumulative returns. The relative divergence, which indicates the current position within the historical range of performance difference, stands at 65.53%, suggesting that ABBV's performance has been relatively strong compared to its historical performance against VOO.

**2. Recent Price Action:**

* **Closing Price:** 196.31
* **5-Day Moving Average:** 196.05
* **20-Day Moving Average:** 193.17
* **60-Day Moving Average:** 179.48

The stock is trading above all three moving averages, indicating a bullish trend in the short and medium term.

**3. Technical Indicators:**

* **RSI:** 74.27. This value indicates that the stock is currently in the overbought territory.
* **PPO:** -0.36. The PPO is negative, suggesting a potential slowdown in momentum.
* **Delta_Previous_Relative_Divergence:** -3.27. This negative value indicates a recent decline in the relative divergence, hinting at a possible correction in the short term.
* **Expected_Return:** 16.29%. This is the estimated maximum return potential over the next 5 years for an investment made at the current price.

**4. Recent Earnings Performance and Outlook:**

The company has consistently exceeded earnings estimates in recent quarters.

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

The most recent earnings report for the quarter ending July 25, 2024, shows EPS of 2.65, exceeding the expected EPS of 2.57. This consistent performance suggests a healthy business outlook.

**5. Overall Analysis:**

ABBV has exhibited strong performance, outperforming the S&P 500 in the past. The stock currently displays a bullish short-term trend, indicated by its position above its moving averages. However, technical indicators like RSI and PPO suggest potential for a near-term correction, due to overbought conditions and a slowdown in momentum. Nonetheless, ABBV's consistent track record of exceeding earnings estimates points to a strong underlying business and potentially sustained growth in the long term. The 16.29% expected return reinforces this positive outlook, offering potential for lucrative investment returns over a 5-year horizon.

**6. Conclusion:**

ABBV remains a promising investment option with strong fundamentals and a proven track record of success. While the stock might experience some short-term volatility due to overbought conditions, the long-term prospects remain positive, supported by strong earnings performance, a healthy business outlook, and a compelling expected return. Investors considering a long-term investment strategy should carefully monitor the stock's price action and technical indicators to capitalize on potential opportunities while mitigating potential risks associated with market fluctuations. 
